Cancer Drugs Fund

Future prospects for an Innovative Medicines Fund for England

https://pharmaphorum.com/views-analysis-market-access/future-prospects-for-an-innovative-medicines-fund-for-england/

NICE’s track record in cancer drugs: the impact of the CDF and interim funding

https://pharmaphorum.com/views-and-analysis/nices-track-record-in-cancer-drugs-the-impact-of-the-cdf-and-interim-funding/

Janssen’s Imbruvica runs into trouble with NICE in mantle cell lymphoma

https://pharmaphorum.com/news/imbruvica-mantle-cell-lymphoma/

After a year’s delay, BMS seals Opdivo lung cancer deal with NICE

https://pharmaphorum.com/news/lung-cancer-patients-england-get-opdivo-bms-deal-nice/

NICE close to clearing Cancer Drugs Fund backlog

https://pharmaphorum.com/news/nice-cdf-backlog/

Roche hails 4 year NICE access deal for Gazyvaro

https://pharmaphorum.com/news/roche-hails-4-year-nice-access-deal-gazyvaro/

UK funding of cancer drugs: right, wrong, or just plain confused?

https://pharmaphorum.com/views-and-analysis/uk-funding-cancer-drugs-right-wrong-just-plain-confused/

Lilly’s sarcoma drug Lartruvo recommended via Cancer Drugs Fund

https://pharmaphorum.com/news/lillys-sarcoma-drug-lartruvo-recommended-via-cancer-drugs-fund/

NICE backs Amgen’s Blincyto in rare leukaemia

https://pharmaphorum.com/news/nice-backs-amgens-blincyto-rare-leukaemia/

1 2 3 4

Close in 10 seconds

Pharmaphorum.com

Search